$3.03
3.77%
Nasdaq, Fri, Oct 02 2026.
ISIN
US52187K1016
Symbol
LPTX

Leap Therapeutics, Inc. Stock price

$3.03
+1.35 80.36% 1M
+2.27 296.91% 6M
+1.87 161.21% YTD
+2.30 315.07% 1Y
+1.73 133.08% 3Y
-32.77 91.54% 5Y
-75.57 96.15% 10Y
-75.57 96.15% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
+0.11 3.77%
ISIN
US52187K1016
Symbol
LPTX
Industry

Is Leap Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$18.1m
Shares outstanding
41.4m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
- | -
P/B
-
Financial Health
Equity Ratio
71.4%
Return on Equity
-193.4%
ROCE
-1,090.2%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$5.6m | -
SBC as % of FCF
-
SBC Growth 1Y
7.7%
Share Count Growth 1Y
8.3%
Shareholder Yield
-8.3%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-62.3m
EBIT
$-62.3m
Net Income
$-65.7m
Free Cash Flow | ex SBC
$-60.1m | $-65.7m
Growth
Revenue | estimate
- | -
EBITDA
5.3%
EBIT
5.3%
Net Income
-8.9%
Free Cash Flow
-20.0%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-1.6
FCF per Share
$-1.4
Short interest
5.8%
Employees
52
Rev per Employee
$0.0

Leap Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Leap Therapeutics, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Leap Therapeutics, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Leap Therapeutics, Inc.

Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
19% 19%
-
- Research and Development Expense 51 51
2% 2%
-
-62 -62
5% 5%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -62 -62
5% 5%
-
Net Profit -66 -66
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about Leap Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Head office United States
CEO Mr. Onsi
Employees 52
Founded 2011
Website www.leaptx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today